HFX is an FDA-approved technology and the only paresthesia-free therapy approved by the FDA to treat diabetic neuropathy.
More than 34 million Americans have diabetes, and 20 to 25 percent of people with diabetes develop PDN, painful diabetic neuropathy, according to a May 9 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
